UNH
UnitedHealth Group Inc.NYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Wed, Nov. 30, 12:22 PM
    • Mizuho Securities upgrades UnitedHealth Group (UNH +1%) to Buy from Neutral with a $178 (12% upside) price target. Four other shops have boosted their price targets to $175 - 195.
    • The company expects to earn as much as $9.60 this year with cash flow ops of $11.5B - 12.0B.
    | Wed, Nov. 30, 12:22 PM | 1 Comment
  • Mon, Nov. 28, 5:19 PM
    • Ahead of its investor day tomorrow, UnitedHealth says it expects full-year adjusted EPS of $9.30-$9.60 vs. Street estimates of $9.14.
    • Cash flow from operations is seen at $11.5B-$12B.
    • 2016 adjusted EPS of $8 compares to consensus $8.01.
    • UNH +2% after hours
    | Mon, Nov. 28, 5:19 PM
  • Fri, Nov. 11, 6:52 AM
    • Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $23 (37% upside) from $81.
    • WellCare Health Plans (NYSE:WCG) downgraded to Neutral from Overweight by JPMorgan.
    • Universal Health Services (NYSE:UHS) downgraded to Neutral from Buy by Bank of America. Price target lowered to $135 (12% upside) from $150.
    • UnitedHealth Group (NYSE:UNH) downgraded to Neutral from Buy by Mizuho Securities.
    • Globus Medical (NYSE:GMED) downgraded to Market Perform from Outperform by JMP Securities and William Blair. Downgraded to Market Perform from Outperform by Oppenheimer. Price target lowered to $23 (7% upside) from $29. Downgraded to Market Perform by Citigroup. Price target lowered to $23 (7% upside) from $29.
    • Kindred Healthcare (NYSE:KND) downgraded to Sell from Hold by Stifel Nicolaus. Price target lowered to $5 (19% downside risk) from $10. Downgraded to Sector Perform by RBC Capital Markets and Royal Bank of Canada. Price target lowered to $9 (46% upside) from $16 by both.
    • Impax Laboratories (NASDAQ:IPXL) downgraded to Underperform from Neutral with a $19 (32% upside) price target by Bank of America.
    • BioMarin Pharmaceutical (NASDAQ:BMRN) downgraded to Neutral from Overweight by Piper Jaffray. Price target lowered to $84 (10% downside risk) from $105.
    | Fri, Nov. 11, 6:52 AM | 26 Comments
  • Wed, Nov. 9, 8:29 AM
    • Hospital groups look a bit sickly premarket as investors appear to perceive a less-than-robust future under a Trump presidency.
    • Sampling: (NYSE:HUM-2%; (NYSE:HCA-16%; (NYSE:THC-26%; (NYSE:CYH-18%; (NYSE:UHS-10%; (NYSE:SEM-7%; (NASDAQ:LPNT-12%
    • Healthcare services are weak as well: (NYSE:UNH-3%; (NYSE:MOH-8%; (NASDAQ:AMSG-11%; (NASDAQ:AMED-3%; (NYSE:EVHC-5%
    | Wed, Nov. 9, 8:29 AM | 31 Comments
  • Wed, Nov. 9, 7:11 AM
    • UnitedHealth Group (NYSE:UNH) declares $0.625/share quarterly dividend, in line with previous.
    • Forward yield 1.75%
    • Payable Dec. 13; for shareholders of record Dec. 2; ex-div Nov. 30.
    | Wed, Nov. 9, 7:11 AM
  • Wed, Nov. 9, 3:03 AM
    • Healthcare stocks, the weakest sector this year, may become winners, as Obamacare reforms are set to be "repealed and replaced" and major legislation Clinton proposed is unlikely to be imposed on drugmakers.
    • While Trump hasn't set out a comprehensive alternative to the Affordable Care Act (which may see 22M Americans lose current coverage), he said he'll encourage competition between markets in different states.
    • Insurance stocks: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    • Drugmakers premarket: MYL +5.8%, NVS +3.4%, SNY +2.9%, AZN +2.4%, GSK +1.9%, PFE +1.8%, CELG +1%, ABBV, MRK, BMY, LLY, JNJ, ABT, ACET, ZTS, BIIB, REGN
    • #Election2016
    | Wed, Nov. 9, 3:03 AM | 14 Comments
  • Thu, Nov. 3, 8:33 AM
    • Thinly traded small cap Novocure (NASDAQ:NVCR) is up 6% premarket, albeit on only 2,900 shares, in response to its announcement that UnitedHealthcare (NYSE:UNH) will cover Optune as adjunctive therapy for the treatment of glioblastoma effective January 1, 2017. United administers medical benefit plans covering almost 45M Americans.
    • The inclusion of United increases the total number of Americans who have insurance coverage of Optune to more than 177M.
    • Optune is a non-invasive device that creates alternating "wave-like" electric fields called Tumor Treating Fields (TTFields). It delivers its therapy to brain tumors through four transducer arrays placed on the scalp. In a large clinical study, Optune was as effective as chemo in treating recurrent glioblastoma.
    | Thu, Nov. 3, 8:33 AM
  • Thu, Nov. 3, 8:24 AM
    | Thu, Nov. 3, 8:24 AM | 43 Comments
  • Fri, Oct. 28, 11:22 AM
    • Drug wholesaler McKesson's (MCK -23.2%) lackluster Q3 numbers and softer guidance due to pricing pressure is weighing on the entire drug supply chain. Competitors AmerisourceBergen (ABC -11.9%) and Cardinal Health (CAH -11.2%) report next week.
    • Representative tickers: (ESRX -4.5%)(CVS -3.9%)(WBA -2.7%)(RAD -0.9%)(UNH +0.1%)
    | Fri, Oct. 28, 11:22 AM | 69 Comments
  • Thu, Oct. 27, 3:41 AM
    • Not only are Obamacare premiums on the rise for 2017, deductibles will also be getting more expensive, according to an analysis by insurance comparison site HealthPocket.
    • Deductibles for individuals enrolled in the lowest-priced Obamacare health plans will average more than $6,000 next year, the first time that threshold has been cracked in the three years that Affordable Care Act marketplaces have been in business. Families enrolled in the bronze plans will average deductibles of $12,393.
    • Previously: Obamacare rates up 25% in 2017 (Oct. 25 2016)
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Thu, Oct. 27, 3:41 AM | 42 Comments
  • Wed, Oct. 26, 6:44 PM
    • The FDA's controversial approval of Sarepta Therapeutics' (NASDAQ:SRPT) eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping has translated into a difficult path to insurance coverage.
    • Humana says it will cover the $300K+ cost of therapy only for ambulatory DMD patients. Those who are wheelchair-bound or deteriorate to wheelchair status are apparently out of luck.
    • Anthem (NYSE:ANTM) has declined to cover it at all because it considers eteplirsen experimental despite the OK from the FDA.
    • Aetna (NYSE:AET) and Express Scripts (NASDAQ:ESRX) plan to conduct a full clinical review of the drug before deciding to cover. UnitedHealth Group (NYSE:UNH) is considering coverage with a prior authorization while Cigna (NYSE:CI) has only indicated interest in providing coverage.
    | Wed, Oct. 26, 6:44 PM | 35 Comments
  • Tue, Oct. 25, 2:22 AM
    • The average premium for benchmark 2017 Obamacare insurance plans sold on Healthcare.gov will jump 25% to $302 compared to this year, the biggest increase since the insurance first went on sale in 2013.
    • Seeking to downplay the cost hikes, the administration said that including subsidies 77% of people would be able to find insurance plans with monthly premiums below $100, however, one in five consumers will only have one insurer from which to choose coverage.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Tue, Oct. 25, 2:22 AM | 43 Comments
  • Tue, Oct. 18, 7:07 AM
    • UnitedHealth Group (UNH +0.2%) Q3 results: Revenues: $46,293M (+11.6%); Premiums: $36,142M (+13.7%); Products: $6,696M (+3.3%); Services: $3,264M (+7.5%); Investment and other income: $191M (+12.4%).
    • UnitedHealthcare: $37,177M (+13.3%); Optum: $21,119M (+9.4%).
    • Premiums: UnitedHealthcare Employer & Individual: $13,251M (+11.6%); UnitedHealthcare Medicare & Retirement: $13,927M (+13.5%); UnitedHealthcare Community & State: $8,312M (+12.4%); UnitedHealthcare Global: $1,687M (+31.1%).
    • Medical costs: $29,040M (+12.9%); Operating Income: $3,580M (+18.6%); Net Income: $1,968M (+23.2%); EPS: $2.03 (+23.0%); Non-GAAP EPS: $2.17 (+22.6%); Quick Assets: $15,667M (+21.3%); CF Ops: $11,204M (+79.9%).
    • OptumHealth: $4,332M (+22.7%); OptumInsight: $1,825M (+15.1%); OptumRx: $15,237M (+5.8%).
    • 2016 Guidance: GAAP EPS: ~$7.45 from $7.25 - 7.40; Non-GAAP EPS: ~$8.00 from $7.80 - 7.95.
    • Shares are up 1% premarket.
    | Tue, Oct. 18, 7:07 AM | 3 Comments
  • Tue, Oct. 18, 5:56 AM
    • UnitedHealth Group (NYSE:UNH): Q3 EPS of $2.17 beats by $0.09.
    • Revenue of $46.29B (+11.6% Y/Y) beats by $200M.
    • Shares +0.95% PM.
    • Press Release
    | Tue, Oct. 18, 5:56 AM | 3 Comments
  • Mon, Oct. 17, 5:30 PM
    | Mon, Oct. 17, 5:30 PM | 4 Comments
  • Wed, Sep. 21, 11:20 AM
    | Wed, Sep. 21, 11:20 AM | 45 Comments